Avacincaptad Pegol

CHICAGO — In this video, Clement K. Chan, MD, FACS, discusses highlights from the AAO meeting, including presentations on pegcetacoplan and avacincaptad pegol for the treatment of geographic atrophy.

Avacincaptad pegol may help postpone driving restrictions or loss of driving eligibility in patients with geographic atrophy, according to a post hoc analysis of the GATHER1 and GATHER2 trials.

Pegcetacoplan may be a more effective treatment option than avacincaptad pegol for reducing geographic atrophy lesion growth in patients with age-related macular degeneration.

In this Healio Video Perspective from the ASRS annual meeting, Dilraj Grewal, MD, FASRS, discusses eyes that developed macular neovascularization in the GATHER trials.

SEATTLE — In this video, Eleonora M. Lad, MD, PhD, discusses presentations from the ARVO annual meeting on real-world use of faricimab and the use of pegcetacoplan in the treatment of geographic atrophy.

Durga S. Borkar, MD, MMCi, assistant professor of ophthalmology and director of clinical data science at Duke University Eye Center, discusses recent FDA approvals that have been useful in the treatment of geographic atrophy.

In this Healio Video Perspective from the Macula Society meeting, Dilsher Dhoot, MD, discusses data from three phase 3 trials involving pegcetacoplan and avacincaptad pegol for the treatment of geographic atrophy.

In this Healio Video Perspective from Angiogenesis, Exudation, and Degeneration 2024, Arshad M. Khanani, MD, MA, FASRS, discusses 2-year expanded efficacy data on avacincaptad pegol, or ACP, for geographic atrophy.

In this video, Esther M. Bowie, MD, discusses the results of the GATHER2 trial, presented at the American Academy of Ophthalmology meeting.

In this video, Yasha S. Modi, MD, discusses the 2-year results of the GATHER2 trial, which showed that avacincaptad pegol had a positive effect on geographic atrophy reduction.